tiprankstipranks
GlaxoSmithKline (MX:GSK1N)
:GSK1N
Mexico Market
GSK1N
GlaxoSmithKline
RESEARCH TOOLSreports

GlaxoSmithKline (GSK1N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

GSK1N Analyst Ratings

Hold
15Ratings
Hold
2 Buy
10 Hold
3 Sell
Based on 15 analysts giving stock ratings to
GlaxoSmithKline
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GSK1N Stock 12 Month Forecast

Average Price Target

$482.59
▲(41.94% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is $482.59 with a high forecast of $695.62 and a low forecast of $392.87. The average price target represents a 41.94% change from the last price of $340.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"319":"$319","696":"$696","413.25":"$413.3","507.5":"$507.5","601.75":"$601.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":695.616001416,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$695.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":482.5866766492308,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$482.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":392.87282472,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$392.87</span>\n  </div></div>","useHTML":true}}],"tickPositions":[319,413.25,507.5,601.75,696],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,336.083,363.73938472430774,391.3957694486154,419.0521541729231,446.7085388972308,474.3649236215385,502.0213083458462,529.6776930701539,557.3340777944616,584.9904625187693,612.646847243077,640.3032319673846,667.9596166916924,{"y":695.616001416,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,336.083,347.3525135884024,358.62202717680475,369.89154076520714,381.16105435360953,392.43056794201186,403.70008153041425,414.96959511881664,426.239108707219,437.5086222956213,448.7781358840237,460.0476494724261,471.3171630608284,{"y":482.5866766492308,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,336.083,340.4514480553846,344.81989611076926,349.18834416615385,353.5567922215385,357.9252402769231,362.2936883323077,366.6621363876923,371.0305844430769,375.39903249846157,379.76748055384616,384.13592860923075,388.5043766646154,{"y":392.87282472,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":320.49,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":324.376,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":324.376,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":324.376,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":328.1,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":328.1,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":328.1,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":332.183,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":332.183,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 21</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":332.183,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":336.083,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":336.083,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":336.083,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$695.62Average Price Target$482.59Lowest Price Target$392.87
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on MX:GSK1N
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$462.2
Hold
35.94%
Upside
Reiterated
08/25/26
GlaxoSmithKline (GSK) Gets a Hold from Deutsche Bank
Barclays Analyst forecast on MX:GSK1N
James Gordon CFA
Barclays
Barclays
$439.09
Sell
29.15%
Upside
Reiterated
08/25/26
Barclays Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
Morgan Stanley Analyst forecast on MX:GSK1N
Sarita Kapila
Morgan Stanley
Morgan Stanley
$404.29→$438.94
Sell
29.10%
Upside
Reiterated
08/25/26
Morgan Stanley Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Berenberg Bank Analyst forecast on MX:GSK1N
Kerry Holford
Berenberg Bank
Berenberg Bank
$462.2
Hold
35.94%
Upside
Reiterated
08/17/26
Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Jefferies Analyst forecast on MX:GSK1N
Michael Leuchten
Jefferies
Jefferies
$577.75
Buy
69.93%
Upside
Reiterated
08/11/26
Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
J.P. Morgan Analyst forecast on MX:GSK1N
Zain Ebrahim
J.P. Morgan
J.P. Morgan
$392.87
Sell
15.55%
Upside
Reiterated
08/04/26
J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
Bernstein Analyst forecast on MX:GSK1N
Justin Smith
Bernstein
Bernstein
$652.86→$695.62
Buy
104.59%
Upside
Reiterated
08/03/26
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
DZ BANK AG Analyst forecast on MX:GSK1N
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
07/29/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Citi Analyst forecast on MX:GSK1N
Graham Parry
Citi
Citi
$485.31
Hold
42.74%
Upside
Reiterated
07/29/26
Citi Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Goldman Sachs Analyst forecast on MX:GSK1N
Rajan Sharma
Goldman Sachs
Goldman Sachs
$432.01→$436.63
Hold
28.42%
Upside
Reiterated
07/28/26
GSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90
Bank of America Securities Analyst forecast on MX:GSK1N
Sachin Jain
Bank of America Securities
Bank of America Securities
$542.9
Hold
59.68%
Upside
Reiterated
07/28/26
GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained
UBS Analyst forecast on MX:GSK1N
Matthew Weston
UBS
UBS
$448.34
Hold
31.86%
Upside
Reiterated
07/13/26
UBS Remains a Hold on GlaxoSmithKline (GSK)
Guggenheim Analyst forecast on MX:GSK1N
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
07/09/26
Guggenheim Remains a Hold on GlaxoSmithKline (GSK)
HSBC Analyst forecast on MX:GSK1N
Rajesh Kumar
HSBC
HSBC
$346.53→$429.7
Hold
26.38%
Upside
Upgraded
07/06/26
GSK upgraded to Hold from Reduce at HSBCGSK upgraded to Hold from Reduce at HSBC
Intron Health Analyst forecast on MX:GSK1N
Unknown Analyst
Intron Health
Not Ranked
Intron Health
$462.05
Hold
35.90%
Upside
Upgraded
06/10/26
GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on MX:GSK1N
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$462.2
Hold
35.94%
Upside
Reiterated
08/25/26
GlaxoSmithKline (GSK) Gets a Hold from Deutsche Bank
Barclays Analyst forecast on MX:GSK1N
James Gordon CFA
Barclays
Barclays
$439.09
Sell
29.15%
Upside
Reiterated
08/25/26
Barclays Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
Morgan Stanley Analyst forecast on MX:GSK1N
Sarita Kapila
Morgan Stanley
Morgan Stanley
$404.29→$438.94
Sell
29.10%
Upside
Reiterated
08/25/26
Morgan Stanley Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Berenberg Bank Analyst forecast on MX:GSK1N
Kerry Holford
Berenberg Bank
Berenberg Bank
$462.2
Hold
35.94%
Upside
Reiterated
08/17/26
Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Jefferies Analyst forecast on MX:GSK1N
Michael Leuchten
Jefferies
Jefferies
$577.75
Buy
69.93%
Upside
Reiterated
08/11/26
Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
J.P. Morgan Analyst forecast on MX:GSK1N
Zain Ebrahim
J.P. Morgan
J.P. Morgan
$392.87
Sell
15.55%
Upside
Reiterated
08/04/26
J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
Bernstein Analyst forecast on MX:GSK1N
Justin Smith
Bernstein
Bernstein
$652.86→$695.62
Buy
104.59%
Upside
Reiterated
08/03/26
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
DZ BANK AG Analyst forecast on MX:GSK1N
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
07/29/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Citi Analyst forecast on MX:GSK1N
Graham Parry
Citi
Citi
$485.31
Hold
42.74%
Upside
Reiterated
07/29/26
Citi Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Goldman Sachs Analyst forecast on MX:GSK1N
Rajan Sharma
Goldman Sachs
Goldman Sachs
$432.01→$436.63
Hold
28.42%
Upside
Reiterated
07/28/26
GSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90
Bank of America Securities Analyst forecast on MX:GSK1N
Sachin Jain
Bank of America Securities
Bank of America Securities
$542.9
Hold
59.68%
Upside
Reiterated
07/28/26
GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained
UBS Analyst forecast on MX:GSK1N
Matthew Weston
UBS
UBS
$448.34
Hold
31.86%
Upside
Reiterated
07/13/26
UBS Remains a Hold on GlaxoSmithKline (GSK)
Guggenheim Analyst forecast on MX:GSK1N
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
07/09/26
Guggenheim Remains a Hold on GlaxoSmithKline (GSK)
HSBC Analyst forecast on MX:GSK1N
Rajesh Kumar
HSBC
HSBC
$346.53→$429.7
Hold
26.38%
Upside
Upgraded
07/06/26
GSK upgraded to Hold from Reduce at HSBCGSK upgraded to Hold from Reduce at HSBC
Intron Health Analyst forecast on MX:GSK1N
Unknown Analyst
Intron Health
Not Ranked
Intron Health
$462.05
Hold
35.90%
Upside
Upgraded
06/10/26
GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

3 Months
Michael LeuchtenJefferies
Success Rate
17/31 ratings generated profit
55%
Average Return
+1.55%
Copying Michael Leuchten's trades and holding each position for 3 Months would result in 54.84% of your transactions generating a profit, with an average return of +1.55% per trade.
1 Year
Michael LeuchtenJefferies
Success Rate
20/31 ratings generated profit
65%
Average Return
+4.86%
Copying Michael Leuchten's trades and holding each position for 1 Year would result in 64.52% of your transactions generating a profit, with an average return of +4.86% per trade.
2 Years
Justin SmithBernstein
Success Rate
14/22 ratings generated profit
64%
Average Return
+9.86%
Copying Justin Smith's trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +9.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GSK1N Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
1
Buy
10
7
8
9
7
Hold
21
19
25
28
25
Sell
21
18
16
16
19
Strong Sell
0
0
0
0
0
total
52
44
49
53
52
In the current month, GSK1N has received 8 Buy Ratings, 25 Hold Ratings, and 19 Sell Ratings. GSK1N average Analyst price target in the past 3 months is 482.59.
Each month's total comprises the sum of three months' worth of ratings.

GSK1N Financial Forecast

GSK1N Earnings Forecast

Next quarter’s earnings estimate for GSK1N is $11.87 with a range of $11.06 to $12.65. The previous quarter’s EPS was $11.64. GSK1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GSK1N has Performed in-line its overall industry.
Next quarter’s earnings estimate for GSK1N is $11.87 with a range of $11.06 to $12.65. The previous quarter’s EPS was $11.64. GSK1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GSK1N has Performed in-line its overall industry.

GSK1N Sales Forecast

Next quarter’s sales forecast for GSK1N is $204.58B with a range of $201.36B to $208.08B. The previous quarter’s sales results were $193.75B. GSK1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GSK1N has Performed in-line its overall industry.
Next quarter’s sales forecast for GSK1N is $204.58B with a range of $201.36B to $208.08B. The previous quarter’s sales results were $193.75B. GSK1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GSK1N has Performed in-line its overall industry.

GSK1N Stock Forecast FAQ

What is MX:GSK1N’s average 12-month price target, according to analysts?
Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 482.59.
    What is MX:GSK1N’s upside potential, based on the analysts’ average price target?
    GlaxoSmithKline has 41.94% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GlaxoSmithKline a Buy, Sell or Hold?
          GlaxoSmithKline has a consensus rating of Hold, which is based on 2 buy ratings, 10 hold ratings and 3 sell ratings.
            What is GlaxoSmithKline’s share price target?
            The average share price target for GlaxoSmithKline is 482.59. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $695.62 ,and the lowest forecast is $392.87. The average share price target represents 41.94% Increase from the current price of $340.
              What do analysts say about GlaxoSmithKline?
              GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of GlaxoSmithKline?
                To buy shares of MX:GSK1N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.